Tramadol hydrochloride: Pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems
Abstract Tramadol hydrochloride (TrHC) is a synthetic analgesic drug exhibiting opioid and non-opioid properties, acting mainly on the central nervous system. It has been mostly used to treat pain, although its use to treat anxiety and depression has also been documented. These properties arise from...
Gespeichert in:
| Veröffentlicht in: | Biomedicine & pharmacotherapy 2015-03, Vol.70 (C), p.234-238 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 238 |
|---|---|
| container_issue | C |
| container_start_page | 234 |
| container_title | Biomedicine & pharmacotherapy |
| container_volume | 70 |
| creator | Vazzana, M Andreani, T Fangueiro, J Faggio, C Silva, C Santini, A Garcia, M.L Silva, A.M Souto, E.B |
| description | Abstract Tramadol hydrochloride (TrHC) is a synthetic analgesic drug exhibiting opioid and non-opioid properties, acting mainly on the central nervous system. It has been mostly used to treat pain, although its use to treat anxiety and depression has also been documented. These properties arise from the fact that they inhibit serotonin (5-HT) reuptake augmenting 5-HT concentration on the synaptic cleft. Despite this, TrHC has also been described to have several side effects which are mainly due to its fast metabolization and excretion which in turn requires multiple doses per day. To surpass this limitation, new pharmaceutical formulations are being developed intending the protection, target and sustained delivery as well as a reduction on daily dose aiming a reduction on the side effects. In the present work we have revised the efficacy, safety, biological and adverse effects of TrHC, and the added value of developing a novel drug delivery system for topical administration. |
| doi_str_mv | 10.1016/j.biopha.2015.01.022 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_2279296</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332215000396</els_id><sourcerecordid>1678746574</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-e9d8b4ed20bae1d65c9449ad9f7ac2eeb3c5b5359cf4c3ea380f45ce588d2763</originalsourceid><addsrcrecordid>eNqFUsuO1DAQtBCIHRb-ACGLEwcy-BHHCYeV0IqXtBJIzN1y7A7xbGIPdrIov8BX42wGDlw4WW5VdZeqCqHnlOwpodWb47514dTrPSNU7AndE8YeoB1tBCkqQuRDtCNS8IJzxi7Qk5SOhBBR8foxumBCykqQaod-HaIetQ0D7hcbg-mHEJ2Ft_hrr-OoTbh1HiZn0mt8Ok_s4vV4P9H2DmICnDIDQ9eBmfLUhELb0XmXpqgnFzwOHbZx_p6w9hZ7-Hn_wxYGl_kLTkuaYExP0aNODwmend9LdPjw_nD9qbj58vHz9bubwggqpgIaW7clWEZaDdRWwjRl2WjbdFIbBtByI1rBRWO60nDQvCZdKQyIurZMVvwSvdzWhjQ5lYybwPQmeJ_VK8Zkw5oV9GoDnWL4MUOa1OiSgWHQHsKcFK1kLctKyDJDyw1qYkgpQqdO0Y06LooStSaljmpLSq1JKUJVTirTXpwvzO0I9i_pTzQZcLUBIHtx5yCuWsEbsC6uUm1w_7vw7wIz5FSMHm5hgXQMc_TZZ0VVYoqob2tb1rJQkYvCswm_Acg7vrM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1678746574</pqid></control><display><type>article</type><title>Tramadol hydrochloride: Pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Vazzana, M ; Andreani, T ; Fangueiro, J ; Faggio, C ; Silva, C ; Santini, A ; Garcia, M.L ; Silva, A.M ; Souto, E.B</creator><creatorcontrib>Vazzana, M ; Andreani, T ; Fangueiro, J ; Faggio, C ; Silva, C ; Santini, A ; Garcia, M.L ; Silva, A.M ; Souto, E.B</creatorcontrib><description>Abstract Tramadol hydrochloride (TrHC) is a synthetic analgesic drug exhibiting opioid and non-opioid properties, acting mainly on the central nervous system. It has been mostly used to treat pain, although its use to treat anxiety and depression has also been documented. These properties arise from the fact that they inhibit serotonin (5-HT) reuptake augmenting 5-HT concentration on the synaptic cleft. Despite this, TrHC has also been described to have several side effects which are mainly due to its fast metabolization and excretion which in turn requires multiple doses per day. To surpass this limitation, new pharmaceutical formulations are being developed intending the protection, target and sustained delivery as well as a reduction on daily dose aiming a reduction on the side effects. In the present work we have revised the efficacy, safety, biological and adverse effects of TrHC, and the added value of developing a novel drug delivery system for topical administration.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2015.01.022</identifier><identifier>PMID: 25776506</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Analgesics, Opioid - administration & dosage ; Analgesics, Opioid - adverse effects ; Analgesics, Opioid - pharmacokinetics ; Animals ; Chemistry, Pharmaceutical - methods ; Dizziness - chemically induced ; Dizziness - metabolism ; Drug delivery ; Drug Delivery Systems - trends ; Humans ; Internal Medicine ; Medical Education ; Pain relief ; Pharmaceutical Preparations - administration & dosage ; Pharmaceutical Preparations - metabolism ; Polyacrylates ; Solid lipid nanoparticles ; Tramadol - administration & dosage ; Tramadol - adverse effects ; Tramadol - pharmacokinetics ; Tramadol hydrochloride</subject><ispartof>Biomedicine & pharmacotherapy, 2015-03, Vol.70 (C), p.234-238</ispartof><rights>Elsevier Masson SAS</rights><rights>2015 Elsevier Masson SAS</rights><rights>Copyright © 2015 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c515t-e9d8b4ed20bae1d65c9449ad9f7ac2eeb3c5b5359cf4c3ea380f45ce588d2763</citedby><cites>FETCH-LOGICAL-c515t-e9d8b4ed20bae1d65c9449ad9f7ac2eeb3c5b5359cf4c3ea380f45ce588d2763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biopha.2015.01.022$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25776506$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/2279296$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Vazzana, M</creatorcontrib><creatorcontrib>Andreani, T</creatorcontrib><creatorcontrib>Fangueiro, J</creatorcontrib><creatorcontrib>Faggio, C</creatorcontrib><creatorcontrib>Silva, C</creatorcontrib><creatorcontrib>Santini, A</creatorcontrib><creatorcontrib>Garcia, M.L</creatorcontrib><creatorcontrib>Silva, A.M</creatorcontrib><creatorcontrib>Souto, E.B</creatorcontrib><title>Tramadol hydrochloride: Pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems</title><title>Biomedicine & pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Abstract Tramadol hydrochloride (TrHC) is a synthetic analgesic drug exhibiting opioid and non-opioid properties, acting mainly on the central nervous system. It has been mostly used to treat pain, although its use to treat anxiety and depression has also been documented. These properties arise from the fact that they inhibit serotonin (5-HT) reuptake augmenting 5-HT concentration on the synaptic cleft. Despite this, TrHC has also been described to have several side effects which are mainly due to its fast metabolization and excretion which in turn requires multiple doses per day. To surpass this limitation, new pharmaceutical formulations are being developed intending the protection, target and sustained delivery as well as a reduction on daily dose aiming a reduction on the side effects. In the present work we have revised the efficacy, safety, biological and adverse effects of TrHC, and the added value of developing a novel drug delivery system for topical administration.</description><subject>Analgesics, Opioid - administration & dosage</subject><subject>Analgesics, Opioid - adverse effects</subject><subject>Analgesics, Opioid - pharmacokinetics</subject><subject>Animals</subject><subject>Chemistry, Pharmaceutical - methods</subject><subject>Dizziness - chemically induced</subject><subject>Dizziness - metabolism</subject><subject>Drug delivery</subject><subject>Drug Delivery Systems - trends</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medical Education</subject><subject>Pain relief</subject><subject>Pharmaceutical Preparations - administration & dosage</subject><subject>Pharmaceutical Preparations - metabolism</subject><subject>Polyacrylates</subject><subject>Solid lipid nanoparticles</subject><subject>Tramadol - administration & dosage</subject><subject>Tramadol - adverse effects</subject><subject>Tramadol - pharmacokinetics</subject><subject>Tramadol hydrochloride</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUsuO1DAQtBCIHRb-ACGLEwcy-BHHCYeV0IqXtBJIzN1y7A7xbGIPdrIov8BX42wGDlw4WW5VdZeqCqHnlOwpodWb47514dTrPSNU7AndE8YeoB1tBCkqQuRDtCNS8IJzxi7Qk5SOhBBR8foxumBCykqQaod-HaIetQ0D7hcbg-mHEJ2Ft_hrr-OoTbh1HiZn0mt8Ok_s4vV4P9H2DmICnDIDQ9eBmfLUhELb0XmXpqgnFzwOHbZx_p6w9hZ7-Hn_wxYGl_kLTkuaYExP0aNODwmend9LdPjw_nD9qbj58vHz9bubwggqpgIaW7clWEZaDdRWwjRl2WjbdFIbBtByI1rBRWO60nDQvCZdKQyIurZMVvwSvdzWhjQ5lYybwPQmeJ_VK8Zkw5oV9GoDnWL4MUOa1OiSgWHQHsKcFK1kLctKyDJDyw1qYkgpQqdO0Y06LooStSaljmpLSq1JKUJVTirTXpwvzO0I9i_pTzQZcLUBIHtx5yCuWsEbsC6uUm1w_7vw7wIz5FSMHm5hgXQMc_TZZ0VVYoqob2tb1rJQkYvCswm_Acg7vrM</recordid><startdate>20150301</startdate><enddate>20150301</enddate><creator>Vazzana, M</creator><creator>Andreani, T</creator><creator>Fangueiro, J</creator><creator>Faggio, C</creator><creator>Silva, C</creator><creator>Santini, A</creator><creator>Garcia, M.L</creator><creator>Silva, A.M</creator><creator>Souto, E.B</creator><general>Elsevier Masson SAS</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>OTOTI</scope></search><sort><creationdate>20150301</creationdate><title>Tramadol hydrochloride: Pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems</title><author>Vazzana, M ; Andreani, T ; Fangueiro, J ; Faggio, C ; Silva, C ; Santini, A ; Garcia, M.L ; Silva, A.M ; Souto, E.B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-e9d8b4ed20bae1d65c9449ad9f7ac2eeb3c5b5359cf4c3ea380f45ce588d2763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Analgesics, Opioid - administration & dosage</topic><topic>Analgesics, Opioid - adverse effects</topic><topic>Analgesics, Opioid - pharmacokinetics</topic><topic>Animals</topic><topic>Chemistry, Pharmaceutical - methods</topic><topic>Dizziness - chemically induced</topic><topic>Dizziness - metabolism</topic><topic>Drug delivery</topic><topic>Drug Delivery Systems - trends</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medical Education</topic><topic>Pain relief</topic><topic>Pharmaceutical Preparations - administration & dosage</topic><topic>Pharmaceutical Preparations - metabolism</topic><topic>Polyacrylates</topic><topic>Solid lipid nanoparticles</topic><topic>Tramadol - administration & dosage</topic><topic>Tramadol - adverse effects</topic><topic>Tramadol - pharmacokinetics</topic><topic>Tramadol hydrochloride</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vazzana, M</creatorcontrib><creatorcontrib>Andreani, T</creatorcontrib><creatorcontrib>Fangueiro, J</creatorcontrib><creatorcontrib>Faggio, C</creatorcontrib><creatorcontrib>Silva, C</creatorcontrib><creatorcontrib>Santini, A</creatorcontrib><creatorcontrib>Garcia, M.L</creatorcontrib><creatorcontrib>Silva, A.M</creatorcontrib><creatorcontrib>Souto, E.B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>Biomedicine & pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vazzana, M</au><au>Andreani, T</au><au>Fangueiro, J</au><au>Faggio, C</au><au>Silva, C</au><au>Santini, A</au><au>Garcia, M.L</au><au>Silva, A.M</au><au>Souto, E.B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tramadol hydrochloride: Pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems</atitle><jtitle>Biomedicine & pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2015-03-01</date><risdate>2015</risdate><volume>70</volume><issue>C</issue><spage>234</spage><epage>238</epage><pages>234-238</pages><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Abstract Tramadol hydrochloride (TrHC) is a synthetic analgesic drug exhibiting opioid and non-opioid properties, acting mainly on the central nervous system. It has been mostly used to treat pain, although its use to treat anxiety and depression has also been documented. These properties arise from the fact that they inhibit serotonin (5-HT) reuptake augmenting 5-HT concentration on the synaptic cleft. Despite this, TrHC has also been described to have several side effects which are mainly due to its fast metabolization and excretion which in turn requires multiple doses per day. To surpass this limitation, new pharmaceutical formulations are being developed intending the protection, target and sustained delivery as well as a reduction on daily dose aiming a reduction on the side effects. In the present work we have revised the efficacy, safety, biological and adverse effects of TrHC, and the added value of developing a novel drug delivery system for topical administration.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>25776506</pmid><doi>10.1016/j.biopha.2015.01.022</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0753-3322 |
| ispartof | Biomedicine & pharmacotherapy, 2015-03, Vol.70 (C), p.234-238 |
| issn | 0753-3322 1950-6007 |
| language | eng |
| recordid | cdi_osti_scitechconnect_2279296 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Analgesics, Opioid - administration & dosage Analgesics, Opioid - adverse effects Analgesics, Opioid - pharmacokinetics Animals Chemistry, Pharmaceutical - methods Dizziness - chemically induced Dizziness - metabolism Drug delivery Drug Delivery Systems - trends Humans Internal Medicine Medical Education Pain relief Pharmaceutical Preparations - administration & dosage Pharmaceutical Preparations - metabolism Polyacrylates Solid lipid nanoparticles Tramadol - administration & dosage Tramadol - adverse effects Tramadol - pharmacokinetics Tramadol hydrochloride |
| title | Tramadol hydrochloride: Pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T14%3A13%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tramadol%20hydrochloride:%20Pharmacokinetics,%20pharmacodynamics,%20adverse%20side%20effects,%20co-administration%20of%20drugs%20and%20new%20drug%20delivery%20systems&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Vazzana,%20M&rft.date=2015-03-01&rft.volume=70&rft.issue=C&rft.spage=234&rft.epage=238&rft.pages=234-238&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2015.01.022&rft_dat=%3Cproquest_osti_%3E1678746574%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1678746574&rft_id=info:pmid/25776506&rft_els_id=S0753332215000396&rfr_iscdi=true |